The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Michael, D R ^a   Davies, T S ^a   Moss, J W E ^b   Lama Calvente, D ^a   Ramji, D P ^b   Marchesi, J R ^b,c   Pechlivanis, A ^c   Plummer, S F ^a   Hughes, T R ^d  

^a CULTECH LTD   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CHOLESTEROL; CYTOKINE; HYPOCHOLESTEROLEMIC AGENT; LIPID; PROBIOTIC AGENT;

ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; CACO-2 CELL LINE; COLON; DRUG EFFECT; HUMAN; LACTOBACILLUS PLANTARUM; LIPID DIET; LIVER; METABOLISM; MICROBIAL CONSORTIUM; MICROBIOLOGY; MOUSE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; BODY WEIGHT; CACO-2 CELLS; CHOLESTEROL; COLON; CYTOKINES; DIET, HIGH-FAT; HUMANS; LACTOBACILLUS PLANTARUM; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MICROBIAL CONSORTIA; PROBIOTICS;

EID: 85020405656     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-02889-5     Document Type: Article

References (58)

1. Bhatnagar, P., Wickramasinghe, K., Williams, J., Rayner, M., & Townsend, N. The epidemiology of cardiovascular disease in the UK 2014. Heart 101, 1182-1189, doi:10.1136/heartjnl-2015-307516 (2015).
2. WHO. World Health Organisation, Fact Sheet 317 (2015).
3. McLaren, J. E., Michael, D. R., Ashlin, T. G., & Ramji, D. P. Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Prog Lipid Res 50, 331-347, doi:1016/j.plipres.2011.04.002 (2011).
4. Taylor, F., et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1, CD004816, doi:10.1002/14651858.CD004816.pub5 (2013).
5. Buckley, M. L., & Ramji, D. P. The influence of dysfunctional signaling and lipid homeostasis in mediating the inflammatory responses during atherosclerosis. Biochim Biophys Acta 1852, 1498-1510, doi:10.1016/j.bbadis.2015.04.011 (2015).
6. Michael, D. R., Ashlin, T. G., Buckley, M. L., & Ramji, D. P. Macrophages, lipid metabolism and gene expression in atherogenesis: a therapeutic target of the future?. Clinical Lipidology 7, 37-48, doi:10.2217/clp.11.73 (2012).
7. Moss, J. W., & Ramji, D. P. Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol 13, 513-532, doi:10.1038/nrcardio.2016.103 (2016).
8. Banach, M., et al. Statin intolerance - An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 11, 1-23, doi:10.5114/aoms.2015.49807 (2015).
9. Lichtenstein, A. H., et al. Summary of American Heart Association Diet and Lifestyle Recommendations revision 2006. Arterioscler Thromb Vasc Biol 26, 2186-2191, doi:10.1161/01.ATV.0000238352.25222.5e (2006).
10. Christie, C. Proposed Dietary Guidelines 2015 and Implications for Cardiovascular Disease and Diabetes. J Cardiovasc Nurs 30, 375-378, doi:10.1097/JCN.0000000000000286 (2015).
11. Ramsay, L. E., Yeo, W. W., & Jackson, P. R. Dietary reduction of serum cholesterol concentration: time to think again. BMJ 303, 953-957 (1991).
12. Berger, S., Raman, G., Vishwanathan, R., Jacques, P. F., & Johnson, E. J. Dietary cholesterol and cardiovascular disease: a systematic review and meta-Analysis. Am J Clin Nutr 102, 276-294, doi:10.3945/ajcn.114.100305 (2015).
13. Hill, C., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11, 506-514, doi:10.1038/nrgastro.2014.66 (2014).
14. FAO/WHO. Probiotics in food: health and nutritional properties and guidelines for evaluation: report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food, including powder milk with live lactic acid bacteria: Cordoba, Argentina, 1-4 October 2001: report of a Joint FAO/WHO Working Group on Drafting Guidelines for the Evaluation of Probiotics in Food (Food and Agriculture Organization of the United Nations, 2006).
15. DiRienzo, D. B. Effect of probiotics on biomarkers of cardiovascular disease: implications for heart-healthy diets. Nutr Rev 72, 18-29, doi:10.1111/nure.12084 (2014).
16. Sun, J., & Buys, N. Effects of probiotics consumption on lowering lipids and CVD risk factors: A systematic review and meta-Analysis of randomized controlled trials. Ann Med 47, 430-440, doi:10.3109/07853890.2015.1071872 (2015).
17. Guo, Z., et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-Analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis 21, 844-850, doi:10.1016/j.numecd.2011.04.008 (2011).
18. Fuentes, M. C., Lajo, T., Carrión, J. M., & Cuñé, J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br J Nutr 109, 1866-1872, doi:10.1017/S000711451200373X (2013).
19. Madjd, A., et al. Comparison of the effect of daily consumption of probiotic compared with low-fat conventional yogurt on weight loss in healthy obese women following an energy-restricted diet: a randomized controlled trial. Am J Clin Nutr 103, 323-329, doi:10.3945/ajcn.115.120170 (2016).
20. Rajkumar, H., et al. Effect of Probiotic Lactobacillus salivarius UBL S22 and Prebiotic Fructo-oligosaccharide on Serum Lipids, Inflammatory Markers, Insulin Sensitivity, and Gut Bacteria in Healthy Young Volunteers: A Randomized Controlled Single-Blind Pilot Study. J Cardiovasc Pharmacol Ther 20, 289-298, doi:10.1177/1074248414555004 (2015).
21. Shimizu, M., Hashiguchi, M., Shiga, T., Tamura, H. O., & Mochizuki, M. Meta-Analysis: Effects of Probiotic Supplementation on Lipid Profiles in Normal to Mildly Hypercholesterolemic Individuals. PLoS One 10, e013979, doi:10.1371/journal.pone.0139795 (2015).
22. Pereira, D. I., & Gibson, G. R. Cholesterol assimilation by lactic acid bacteria and bifidobacteria isolated from the human gut. Appl Environ Microbiol 68, 4689-4693 (2002).
23. Kumar, M., et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012, 902917, doi:10.1155/2012/902917 (2012).
24. Begley, M., Hill, C., & Gahan, C. G. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 72, 1729-1738, doi:10.1128/.AEM.72.3.1729-1738.2006 (2006).
25. Yoon, H. S., et al. Reduction in cholesterol absorption in Caco-2 cells through the down-regulation of Niemann-Pick C1-like 1 by the putative probiotic strains Lactobacillus rhamnosus BFE5264 and Lactobacillus plantarum NR74 from fermented foods. Int J Food Sci Nutr 64, 44-52, doi:10.3109/09637486.2012.706598 (2013).
26. Gorenjak, M., et al. Improvement of lipid profile by probiotic/protective cultures: study in a non-carcinogenic small intestinal cell model. New Microbiol 37, 51-64 (2014).
27. Huang, Y., & Zheng, Y. The probiotic Lactobacillus acidophilus reduces cholesterol absorption through the down-regulation of Niemann-Pick C1-like 1 in Caco-2 cells. Br J Nutr 103, 473-478, doi:10.1017/S0007114509991991 (2010).
28. Huang, Y., et al. Characterization of Lactobacillus plantarum Lp27 isolated from Tibetan kefir grains: a potential probiotic bacterium with cholesterol-lowering effects. J Dairy Sci 96, 2816-2825, doi:10.3168/jds.2012-6371 (2013).
29. Michael, D. R., et al. Lactobacillus plantarum CUL66 can impact cholesterol homeostasis in Caco-2 enterocytes. Benef Microbes 1-10, doi:10.3920/BM2015.0146 (2016).
30. Williams, E. A., et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 29, 97-103, doi:10.1111/j.1365-2036.2008.03848.x (2009).
31. Garaiova, I., et al. Probiotics and vitamin C for the prevention of respiratory tract infections in children attending preschool: a randomised controlled pilot study. Eur J Clin Nutr 69, 373-379, doi:10.1038/ejcn.2014.174 (2015).
32. Allen, S. J., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-Associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382, 1249-1257, doi:10.1016/S0140-6736(13)61218-0 (2013).
33. Allen, S. J., et al. Probiotics in the prevention of eczema: a randomised controlled trial. Arch Dis Child 99, 1014-1019, doi:10.1136/.archdischild-2013-305799 (2014).
34. Cano, P. G., Santacruz, A., Trejo, F. M., & Sanz, Y. Bifidobacterium CECT 7765 improves metabolic and immunological alterations associated with obesity in high-fat diet-fed mice. Obesity (Silver Spring) 21, 2310-2321, doi:10.1002/oby.20330 (2013).
35. Damodharan, K., Lee, Y. S., Palaniyandi, S. A., Yang, S. H., & Suh, J. W. Preliminary probiotic and technological characterization of Pediococcus pentosaceus strain KID7 and in vivo assessment of its cholesterol-lowering activity. Front Microbiol 6, 768, doi:10.3389/.fmicb.2015.00768 (2015).
36. Kondo, S., et al. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with high-fat diet-induced obesity. Biosci Biotechnol Biochem 74, 1656-1661, doi:10.1271/bbb.100267 (2010).
37. Song, M., et al. Effect of Lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice. J Dairy Sci 98, 1492-1501, doi:10.3168/jds.2014-8586 (2015).
38. Wu, C. C., et al. Effect of Lactobacillus plantarum Strain K21 on High-Fat Diet-Fed Obese Mice. Evid Based Complement Alternat Med 2015, 391767, doi:10.1155/2015/391767 (2015).
39. Park, D. Y., et al. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 8, e59470, doi:10.1371/journal.pone.0059470 (2013).
40. Yoo, S. R., et al. Probiotics L. plantarum and L. curvatus in combination alter hepatic lipid metabolism and suppress diet-induced obesity. Obesity (Silver Spring) 21, 2571-2578, doi:10.1002/oby.20428 (2013).
41. Tanaka, H., Doesburg, K., Iwasaki, T., & Mierau, I. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 82, 2530-2535, doi:10.3168/jds.S0022-0302(99)75506-2 (1999).
42. Tomaro-Duchesneau, C., et al. Cholesterol assimilation by Lactobacillus probiotic bacteria: an in vitro investigation. Biomed Res Int 2014, 380316, doi:10.1155/2014/380316 (2014).
43. Shehata, M. G., El Sohaimy, S. A., El-Sahn, M. A., & Youssef, M. M. Screening of isolated potential probiotic lactic acid bacteria for cholesterol lowering property and bile salt hydrolase activity. Annals of Agricultural Sciences 61, 65-75, doi:10.1016/j.aoas.2016.03.001 (2016).
44. Pavlovic, N., Stankov, K., & Mikov, M. Probiotics-interactions with bile acids and impact on cholesterol metabolism. Appl Biochem Biotechnol 168, 1880-1895, doi:10.1007/s12010-012-9904-4 (2012).
45. Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., & Moschetta, A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep 7, 12-18, doi:10.1016/j.celrep.2014.02.032 (2014).
46. Goodwin, B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 6, 517-526 (2000).
47. Chen, Q., Wang, E., Ma, L., & Zhai, P. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis 11, 56, doi:10.1186/1476-511X-11-56 (2012).
48. Chen, M. L., et al. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota. MBio 7, e02210-02215, doi:10.1128/mBio.02210-15 (2016).
49. Jeun, J., et al. Hypocholesterolemic effects of Lactobacillus plantarum KCTC3928 by increased bile acid excretion in C57BL/6 mice. Nutrition 26, 321-330, doi:10.1016/j.nut.2009.04.011 (2010).
50. Stroeve, J. H., et al. Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice. Lab Invest 90, 1457-1467, doi:10.1038/labinvest.2010.107 (2010).
51. Inagaki, T., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2, 217-225, doi:10.1016/j.cmet.2005.09.001 (2005).
52. Engelking, L. J., McFarlane, M. R., Li, C. K., & Liang, G. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes. J Lipid Res 53, 1359-1368, doi:10.1194/jlr.M027599 (2012).
53. Catry, E., et al. Ezetimibe and simvastatin modulate gut microbiota and expression of genes related to cholesterol metabolism. Life Sci 132, 77-84, doi:10.1016/j.lfs.2015.04.004 (2015).
54. Telford, D. E., et al. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 48, 699-708, doi:10.1194/jlr.M600439-JLR200 (2007).
55. Ooi, L. G., & Liong, M. T. Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. Int J Mol Sci 11, 2499-2522, doi:10.3390/ijms11062499 (2010).
56. Kurdi, P., et al. Cholic acid accumulation and its diminution by short-chain fatty acids in bifidobacteria. Microbiology 149, 2031-2037, doi:10.1099/mic.0.26376-0 (2003).
57. Kurdi, P., et al. Cholic acid is accumulated spontaneously, driven by membrane deltapH, in many lactobacilli. J Bacteriol 182, 6525-6528 (2000).
58. Sarafian, M. H., et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal Chem 87, 9662-9670, doi:10.1021/acs.analchem.5b01556 (2015).